A University of Oxford study published in The BMJ finds users of GLP-1 drugs like Ozempic regain weight and reverse heart ...

Use of the diabetes drug Ozempic for weight loss is rising. Understand the research, how it works, who should use it, and ...

Peanut butter is one of those foods that almost everyone has a strong opinion about. For some, it’s a go-to source of comfort ...

Obesity is a chronic relapsing condition, and treatment options need to reflect this reality, write Sam West, Dimitrios A Koutoukidis, and Susan A Jebb The use of glucagon-like peptide-1 (GLP-1) ...

Celebrities have been striving for health in 2025, with many dropping significant amounts of weight — in many cases with the help of GLP-1 medications like Ozempic. Below are four A-list stars who ...

GLP-1 medications have dominated the weight-loss landscape this year — but some older Americans are reportedly kicking the trend to the curb. A study published in JAMA in January 2025 — which looked ...

The blockbuster weight-loss drug semaglutide and its rivals promise to help reverse the global obesity epidemic – if only more of the people who would benefit from these treatments could afford them.

A major health scare is often the strongest motivator for people to make lifestyle changes. Successfully changing long-term habits requires a firm decision rather than simply wanting to change. Making ...

The best weight loss supplements for women may include magnesium, caffeine, green tea, protein, fiber, and vitamin B12. The FDA doesn’t closely regulate supplements, so they’re not guaranteed to be ...

The FDA approved a pill version of the GLP-1 receptor agonist semaglutide (Wegovy), making it the first oral GLP-1 agent indicated for weight loss, Novo Nordisk announced on Monday. The once-daily 25 ...

Weight-loss pills that harness the same mechanism as the wildly popular drugs Wegovy and Ozempic are coming to the U.S. On Monday Novo Nordisk announced that the U.S. Food and Drug Administration ...

The FDA approved oral semaglutide (Wegovy) for weight loss and reducing major adverse cardiovascular events. Novo Nordisk plans to launch the once-daily oral semaglutide in the US in early January ...